Given that chidamide is continuously administered orally in a phase II clinical trial in patients with peripheral T-cell lymphoma (PTCL) or cutaneous T-cell lymphoma (CTCL) (not published data), we speculate that continuous chidamide administration may keep a prolonged upregulation of PRAME, facilitating the activation, proliferation, differentiation, recognition, and killing of AML cells by PRAME-specific T cells. This evidence concerns the gene PRAME and mature T-cell and NK-cell non-Hodgkin lymphoma.